FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042203075> ?p ?o ?g. }

• W2042203075 endingPage "1111" @default.
• W2042203075 startingPage "1105" @default.
• W2042203075 abstract "Background & AimsThe ability to identify children with CD who are at highest risk for rapid progression from uncomplicated to complicated phenotypes would be invaluable in guiding initial therapy. The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression.MethodsSera were collected from 796 pediatric CD cases and tested for anti-Cbir1 (flagellin), anti–outer membrane protein C, anti–Saccharomyces cerevisiae, and perinuclear antineutrophil cytoplasmic antibody by using enzyme-linked immunosorbent assay. Genotyping (Taqman MGB) was performed for 3 CARD15 variants (single nucleotide polymorphisms 8, 12, and 13). Associations between immune responses (antibody sum and quartile sum score, CARD15, and clinical phenotype were evaluated.ResultsThirty-two percent of patients developed at least 1 disease complication within a median of 32 months, and 18% underwent surgery. The frequency of internal penetrating, stricturing, and surgery significantly increased (P trend < .0001 for all 3 outcomes) with increasing antibody sum and quartile sum score. Nine percent of seropositive groups had internal penetrating/stricturing versus 2.9% in the seronegative group (P = .01). Twelve percent of seropositive groups underwent surgery versus 2% in the seronegative group (P = .0001). The highest antibody sum group (3) and quartile sum score group (4) demonstrated the most rapid disease progression (P < .0001). Increased hazard ratio was observed for antibody sum group 3 (7.8; confidence interval, 2.2–28.7), P < .002 and quartile sum score group 4 (11.0; confidence interval, 1.5–83.0, P < .02).ConclusionsThe rate of complicated CD increases in children as the number and magnitude of immune reactivity increase. Disease progression is significantly faster in children expressing immune reactivity. The ability to identify children with CD who are at highest risk for rapid progression from uncomplicated to complicated phenotypes would be invaluable in guiding initial therapy. The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression. Sera were collected from 796 pediatric CD cases and tested for anti-Cbir1 (flagellin), anti–outer membrane protein C, anti–Saccharomyces cerevisiae, and perinuclear antineutrophil cytoplasmic antibody by using enzyme-linked immunosorbent assay. Genotyping (Taqman MGB) was performed for 3 CARD15 variants (single nucleotide polymorphisms 8, 12, and 13). Associations between immune responses (antibody sum and quartile sum score, CARD15, and clinical phenotype were evaluated. Thirty-two percent of patients developed at least 1 disease complication within a median of 32 months, and 18% underwent surgery. The frequency of internal penetrating, stricturing, and surgery significantly increased (P trend < .0001 for all 3 outcomes) with increasing antibody sum and quartile sum score. Nine percent of seropositive groups had internal penetrating/stricturing versus 2.9% in the seronegative group (P = .01). Twelve percent of seropositive groups underwent surgery versus 2% in the seronegative group (P = .0001). The highest antibody sum group (3) and quartile sum score group (4) demonstrated the most rapid disease progression (P < .0001). Increased hazard ratio was observed for antibody sum group 3 (7.8; confidence interval, 2.2–28.7), P < .002 and quartile sum score group 4 (11.0; confidence interval, 1.5–83.0, P < .02). The rate of complicated CD increases in children as the number and magnitude of immune reactivity increase. Disease progression is significantly faster in children expressing immune reactivity." @default.
• W2042203075 created "2016-06-24" @default.
• W2042203075 creator A5000419484 @default.
• W2042203075 creator A5006726610 @default.
• W2042203075 creator A5009653749 @default.
• W2042203075 creator A5012227761 @default.
• W2042203075 creator A5019018783 @default.
• W2042203075 creator A5019801327 @default.
• W2042203075 creator A5024226928 @default.
• W2042203075 creator A5024924640 @default.
• W2042203075 creator A5025044683 @default.
• W2042203075 creator A5031160507 @default.
• W2042203075 creator A5035425380 @default.
• W2042203075 creator A5035483451 @default.
• W2042203075 creator A5040770914 @default.
• W2042203075 creator A5047783998 @default.
• W2042203075 creator A5051870878 @default.
• W2042203075 creator A5054537181 @default.
• W2042203075 creator A5060024309 @default.
• W2042203075 creator A5061754257 @default.
• W2042203075 creator A5064024135 @default.
• W2042203075 creator A5067218858 @default.
• W2042203075 creator A5067244124 @default.
• W2042203075 creator A5069344994 @default.
• W2042203075 creator A5070035117 @default.
• W2042203075 creator A5077336289 @default.
• W2042203075 creator A5078489127 @default.
• W2042203075 creator A5086034125 @default.
• W2042203075 date "2008-10-01" @default.
• W2042203075 modified "2023-10-18" @default.
• W2042203075 title "Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children" @default.
• W2042203075 cites W1642457845 @default.
• W2042203075 cites W1984353725 @default.
• W2042203075 cites W2022878312 @default.
• W2042203075 cites W2030421888 @default.
• W2042203075 cites W2031310375 @default.
• W2042203075 cites W2038515417 @default.
• W2042203075 cites W2040309911 @default.
• W2042203075 cites W2043780895 @default.
• W2042203075 cites W2046378328 @default.
• W2042203075 cites W2054404048 @default.
• W2042203075 cites W2057842184 @default.
• W2042203075 cites W2058930138 @default.
• W2042203075 cites W2069702840 @default.
• W2042203075 cites W2073439032 @default.
• W2042203075 cites W2100760934 @default.
• W2042203075 cites W2122316223 @default.
• W2042203075 cites W2134617060 @default.
• W2042203075 cites W2159370303 @default.
• W2042203075 cites W2171373302 @default.
• W2042203075 doi "https://doi.org/10.1016/j.cgh.2008.04.032" @default.
• W2042203075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3745777" @default.
• W2042203075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18619921" @default.
• W2042203075 hasPublicationYear "2008" @default.
• W2042203075 type Work @default.
• W2042203075 sameAs 2042203075 @default.
• W2042203075 citedByCount "229" @default.
• W2042203075 countsByYear W20422030752012 @default.
• W2042203075 countsByYear W20422030752013 @default.
• W2042203075 countsByYear W20422030752014 @default.
• W2042203075 countsByYear W20422030752015 @default.
• W2042203075 countsByYear W20422030752016 @default.
• W2042203075 countsByYear W20422030752017 @default.
• W2042203075 countsByYear W20422030752018 @default.
• W2042203075 countsByYear W20422030752019 @default.
• W2042203075 countsByYear W20422030752020 @default.
• W2042203075 countsByYear W20422030752021 @default.
• W2042203075 countsByYear W20422030752022 @default.
• W2042203075 countsByYear W20422030752023 @default.
• W2042203075 crossrefType "journal-article" @default.
• W2042203075 hasAuthorship W2042203075A5000419484 @default.
• W2042203075 hasAuthorship W2042203075A5006726610 @default.
• W2042203075 hasAuthorship W2042203075A5009653749 @default.
• W2042203075 hasAuthorship W2042203075A5012227761 @default.
• W2042203075 hasAuthorship W2042203075A5019018783 @default.
• W2042203075 hasAuthorship W2042203075A5019801327 @default.
• W2042203075 hasAuthorship W2042203075A5024226928 @default.
• W2042203075 hasAuthorship W2042203075A5024924640 @default.
• W2042203075 hasAuthorship W2042203075A5025044683 @default.
• W2042203075 hasAuthorship W2042203075A5031160507 @default.
• W2042203075 hasAuthorship W2042203075A5035425380 @default.
• W2042203075 hasAuthorship W2042203075A5035483451 @default.
• W2042203075 hasAuthorship W2042203075A5040770914 @default.
• W2042203075 hasAuthorship W2042203075A5047783998 @default.
• W2042203075 hasAuthorship W2042203075A5051870878 @default.
• W2042203075 hasAuthorship W2042203075A5054537181 @default.
• W2042203075 hasAuthorship W2042203075A5060024309 @default.
• W2042203075 hasAuthorship W2042203075A5061754257 @default.
• W2042203075 hasAuthorship W2042203075A5064024135 @default.
• W2042203075 hasAuthorship W2042203075A5067218858 @default.
• W2042203075 hasAuthorship W2042203075A5067244124 @default.
• W2042203075 hasAuthorship W2042203075A5069344994 @default.
• W2042203075 hasAuthorship W2042203075A5070035117 @default.
• W2042203075 hasAuthorship W2042203075A5077336289 @default.
• W2042203075 hasAuthorship W2042203075A5078489127 @default.
• W2042203075 hasAuthorship W2042203075A5086034125 @default.
• W2042203075 hasBestOaLocation W20422030751 @default.
• W2042203075 hasConcept C104317684 @default.

• next